ENANTA PHARMACEUTICALS, INC Debt Securities, Available-for-sale, Amortized Cost
ENANTA PHARMACEUTICALS, INC (ENTA) had Debt Securities, Available-for-sale, Amortized Cost of $178.62 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $178.62M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $192.43M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $204.41M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $156.52M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $178.62M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $192.43M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $204.41M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $156.52M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $159.32M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $133.00M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $131.99M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $210.27M 10-K · filed 2025-11-19 |
| 2024-06-30 | $237.09M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $237.05M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $297.37M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $285.31M 10-K · filed 2024-11-27 |
| 2023-06-30 | $298.45M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $153.38M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $201.48M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $237.86M 10-K · filed 2023-11-22 |
| 2022-06-30 | $267.58M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $284.21M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $249.27M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $295.21M 10-K · filed 2022-11-23 |
| 2021-06-30 | $367.81M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $322.87M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $348.77M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $330.92M 10-K · filed 2021-11-24 |
| 2020-06-30 | $333.68M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $360.26M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $386.91M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $348.88M 10-K · filed 2020-11-25 |
| 2019-06-30 | $294.88M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $280.70M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $283.28M 10-Q · filed 2019-02-08 |
| 2018-09-30 | $261.79M 10-K · filed 2019-11-27 |
| 2018-06-30 | $253.84M 10-Q · filed 2018-08-09 |
| 2017-09-30 | $228.21M 10-K · filed 2018-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |